Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

THERANEXUS : PUBLISHES ITS 2021 FINANCIAL AGENDA

12/29/2020 | 09:11am EDT

Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today published its financial agenda for the year 2021.

Publications will take place after the Euronext Paris market close, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary.

1st February 2021: Update on cash 31 December 2020

April 7, 2021: 2020 annual financial results and cash flow update as of March 31, 2021

June 16, 2021: Annual General Meeting

July 8, 2021: Cash flow update at June 30, 2021

September 30, 2021: Financial results for the 1st half 2021

October 19, 2021: Cash flow update at September 30, 2021

In addition, Theranexus plans to participate in the following investor events organized in digital version

January 11-14, 2021: JP Morgan Healthcare (digital)

January 26-27, 2021: Biomed Invest Securities Conference (in digital)

February 10, 2021: CF&B Small and Midcap Event, Paris

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company, from the CEA, which develops drug candidates for the treatment of diseases of the nervous system. THERANEXUS has identified the major role of non-neuronal cells (otherwise called 'glial cells') in the response to psychotropic drugs (targeting neurons). The company is a pioneer in the design and development of drug candidates acting on the interaction between neurons and glial cells. The unique and patented technology exploited by THERANEXUS aims to increase the effectiveness of psychotropic drugs already approved and marketed by combining them with a glial cell modulator.

Proprietary and adaptable, the THERANEXUS platform makes it possible to generate various proprietary drug candidates with high added value in several indications.

THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

Contact:

Tel: +33 (0) 1 53 67 36 70

Email: theranexus@actus.fr

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about THERANEXUS
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
PU
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
AN
04/07THERANEXUS  : Annual results
CO
03/10THERANEXUS  : Extends the capacities of neurolead, its asset screening platform,..
AQ
03/09THERANEXUS  : Theranexus extends the capabilities of neurolead, its active agent..
AN
01/22THERANEXUS  : presents an update on the progress of its main programs and announ..
PU
01/19THERANEXUS  : Provides an update on the progress of its main programs and announ..
AQ
01/18THERANEXUS  : Theranexus presents an update on the progress of its main programs..
AN
01/18THERANEXUS  : 4th quarter earnings
CO
2020THERANEXUS  : Publishes its 2021 financial agenda
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -3,40 M -4,05 M -4,05 M
Net Debt 2020 - - -
P/E ratio 2020 -9,16x
Yield 2020 -
Capitalization 50,9 M 60,6 M 60,5 M
Capi. / Sales 2020 -
EV / Sales 2021 2,75x
Nbr of Employees 17
Free-Float 70,1%
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,50 €
Last Close Price 13,74 €
Spread / Highest target 162%
Spread / Average Target 85,6%
Spread / Lowest Target 45,6%
EPS Revisions
Managers and Directors
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-26.33%61
GILEAD SCIENCES, INC.11.76%81 411
VERTEX PHARMACEUTICALS INCORPORATED-9.62%55 284
WUXI APPTEC CO., LTD.-1.48%49 513
REGENERON PHARMACEUTICALS, INC.-1.64%49 239
BIONTECH SE49.07%29 350